BioSante plans new prostate cancer drug testing
BioSante Pharmaceuticals Inc. said Monday it hopes to restart testing of an experimental prostate cancer drug almost two years after the research was stopped.
Read more on AP via Yahoo! Finance
BioSante plans new prostate cancer drug testing
Long term, tamoxifen stops more cancer than Evista
Long term, tamoxifen stops more cancer than Evista
Longer-term results from a head-to-head trial of two drugs that prevent breast cancer shows that tamoxifen works better than rival Eli Lilly and Co’s Evista, but with a greater risk of some other cancers and blood clots.
Read more on Reuters via Yahoo! News
Related posts
Terramed Alliance News Safe To Treat HER2-positive Breast Cancer
Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin)–typically used in combination with chemotherapy. However, a new study by researchers at Fox Chase Cancer Center reports that it may be safe to treat these patients with both Trastuzumab and adjuvant radiation therapy.
The study will be presented at the annual meeting of the American Society for Radiation Oncology (ASTRO).
» Read more: Terramed Alliance News Safe To Treat HER2-positive Breast Cancer